Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Editas Medicine (EDIT) Operating Expenses (2016 - 2025)

Editas Medicine (EDIT) has disclosed Operating Expenses for 11 consecutive years, with $32.1 million as the latest value for Q3 2025.

  • Quarterly Operating Expenses fell 51.18% to $32.1 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $245.2 million through Sep 2025, down 15.52% year-over-year, with the annual reading at $283.5 million for FY2024, 14.62% up from the prior year.
  • Operating Expenses for Q3 2025 was $32.1 million at Editas Medicine, down from $55.1 million in the prior quarter.
  • The five-year high for Operating Expenses was $84.0 million in Q4 2023, with the low at $32.1 million in Q3 2025.
  • Average Operating Expenses over 5 years is $61.2 million, with a median of $60.6 million recorded in 2022.
  • The sharpest move saw Operating Expenses surged 54.14% in 2024, then crashed 51.18% in 2025.
  • Over 5 years, Operating Expenses stood at $54.1 million in 2021, then grew by 29.41% to $70.0 million in 2022, then grew by 20.05% to $84.0 million in 2023, then fell by 8.11% to $77.2 million in 2024, then tumbled by 58.43% to $32.1 million in 2025.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $32.1 million, $55.1 million, and $80.8 million for Q3 2025, Q2 2025, and Q1 2025 respectively.